99Mtc-Radiolabeled Ge11-Modified Peptide for Ovarian Tumor Targeting Publisher Pubmed



Rahmanian N^{1, 2} ; Hosseinimehr SJ² ; Khalaj A³ ; Noaparast Z² ; Abedi SM⁴ ; Sabzevari O⁵ Show Affiliations
Source: DARU# Journal of Pharmaceutical Sciences Published:2017

Abstract

Background: Ovarian cancer is a serious threat for women health and the early diagnosis of this cancer might improves the survival rate of patients. The use of the targeted radiopharmaceuticals could be a non-invasive and logical method for tumor imaging. The aim of this study was to radiolabel GE11 peptide as a new specific probe for imaging of ovarian tumor. Methods: HYNIC-SSS-GE11 peptide was labeled with 99mTc using tricine as a coligand. The 99mTc-tricine-HYNIC-SSS-GE11 peptide was evaluated for specific cellular binding in three cell lines with different levels of EGFR expression. Tumor targeting was assessed in SKOV3 tumor bearing mice. Results: By using tricine as a coligand, labeling yield was more than 98% and the stability of the radiolabelled peptide in human serum up to 4 h was 96%. The in vitro cell uptake test showed that this radiolabeled peptide had a good affinity to SKOV3 cells with dissociation constant of 73 nM. The in vivo results showed a tumor/muscle ratio of 3.2 at 4 h following injection of 99mTc-tricine-HYNIC-SSS-GE11 peptide. Conclusions: Results of this study showed that 99mTc-tricine-HYNIC-SSS-GE11 peptide could be a promising tool for diagnosis and staging of ovarian cancer. Graphical Abstract: 99mTc-tricine-HYNIC-SSS-GE11, a novl targeted agent for ovarian tumor imaging © 2017 The Author(s).